Cancers, Vol. 12, Pages 1902: ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

Cancers, Vol. 12, Pages 1902: ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer Cancers doi: 10.3390/cancers12071902 Authors: Gaia Griguolo Fara Brasó-Maristany Blanca González-Farré Tomás Pascual Núria Chic Tamara Saurí Ronald Kates Oleg Gluz Débora Martínez Laia Paré Vassilena Tsvetkova David Pesantez Maria Vidal Barbara Adamo Montserrat Muñoz Patricia Galván Laura Barberá Miriam Cuatrecasas Mathias Christgen Hans Kreipe Inés Monge-Escartín Patricia Villagrasa Dolors Soy Tommaso Giarratano Maria Vittoria Dieci Pierfranco Conte Nadia Harbeck Valentina Guarneri Aleix Prat Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA. We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed paraffin-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II t...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research